Publication | Closed Access

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Vitro AssessmentsOncologyMedicineAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyPhase 1Lung Cancer